Intervention of nicotine on MNU-induced bladder cancer in rats

Abstract

This study examined the effect of nicotine on the expression of mutant p53 (mt-p53) in bladder cancer rats. The rat models of bladder cancer were established by infusing N-methyl-nitroso-urea (MNU, 10 mg/kg every 2 weeks for 8 weeks) into the bladder. Pathological examination on the bladder was conducted to confirm the establishment of the model. All the bladder cancer rats were randomly divided into an MNU group and 3 nicotine groups. In the nicotine groups, the rats were intragastrically administered nicotine at different concentrations (25, 15, 5 mg/kg respectively) 3 times per week for 8 weeks. The mt-p53 expression was detected by the immunohistochemical method. The results showed that rat bladder cancer models developed histopathological changes of bladder transitional cell carcinoma. The positive rate of mt-p53 expression in the 3 nicotine groups (25, 15, 5 mg/kg) was 75.00%, 58.33% and 41.67% by the 14th week, respectively, significantly higher than that in the MNU group (33.33%) (all P<0.05). The mt-p53 expression rate was positively correlated with the medication dose and time (P<0.05). It is concluded that nicotine may play an important role in the development of bladder cancer partially by increasing the expression of mt-p53.

Keywords

bladder cancer / nicotine / p53 protein

References

[1] WaldN.J., HackshawA.K.. Cigarette smoking: an epidemiological overview. Br Med Bull, 1996, 52(1): 3-11

[2] GanJ., SkipperP.L., Gago DominguezM., et al.. Alkylaniline-hemoglobin adducts and risk of non-smoking-related bladder cancer. J Natl Cancer Inst, 2004, 96(19): 1425-1431

[3] QianL.X., LiuX.L., DingH., et al.. Dynamic observation on histopathological changes in bladder tumor induced by N-methyl-N-nitrosourea in rats. Chin J Exp Surg (Chinese), 2004, 21(5): 563-564

[4] ChangF.H., LiuS.Z., ManD., et al.. The determination of LD50 of nicotine and empyreumatic oil. Acta Acad Med Nei Mongol (Chinese), 1999, 21(3): 190-191

[5] KnowlesM.A.. Tumor suppressor loci in bladder cancer. Front Biosci, 2007, 12: 2233-2251

[6] LiuY.H., LuoC.L.. Progress in research on p53 gene in bladder cancer. Zhong Guo Gong Ye Yi Xue Za Zhi (Chinese), 2003, 16(1): 37-40

[7] MitraA.P., DatarR.H., CoteR.J.. Molecular staging of bladder cancer. BJU Int, 2005, 96(1): 7-12

[8] Gomez-LazaroM., Fernandez-GomezF.J., JordanJ.. p53: twenty-five years understanding the mechanism of genome protection. J Physiol Biochem, 2004, 60(4): 287-307

[9] AlgabaF., TriasI., SantinelliA., et al.. TP53 in urologic tumors. Anal Quant Cytol Histol, 2003, 25(3): 123-130

[10] YangC.G., ZhangL.J., LiM., et al.. Clinical significance of expression of p53 protein and apoptosis in bladder cancer. Practical J Cancer, 2007, 22(1): 34-36

[11] SyrigosK.N., KarapanagiotouE., HarringtonK.J.. The clinical significance of molecular markers to bladder cancer. Hybrid Hybridomics, 2004, 23(6): 335-342

[12] MoonenP.M., van Balken OryB., KiemeneyL.A., et al.. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol, 2007, 177(1): 80-83

[13] SmithN.D., RubensteinJ.N., EggenerS.E., et al.. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol, 2003, 169(4): 1219-1228

[14] LaRueH., AllardP., SimoneauM., et al.. P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis, 2000, 21(1): 101-106

[15] KelseyK.T., HiraoT., HiraoS., et al.. TP53 alterations and patterns of carcinogen exposure in a U. S. population-based study of bladder cancer. Int J Cancer, 2005, 117(3): 370-375

[16] JemalA., CokkinidesV.E., ShafeyO., et al.. Lung cancer trends in young adults: an early indicator of progress in tobacco control (United States). Cancer Causes Control, 2003, 14(6): 579-585

[17] TsurutaniJ., CastilloS.S., BrognardJ., et al.. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis, 2005, 26(7): 1182-1195

[18] KirkG.D., MerloC., O’DriscollP., et al.. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis, 2007, 45(1): 103-110

[19] Murta-NascimentoC., Schmitz-DrägerB.J., ZeegersM.P., et al.. Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J Urol, 2007, 25(3): 285-295

[20] BjerregaardB.K., Raaschou-NielsenO., SorensenM., et al.. Tobacco smoke and bladder cancer-in the European prospective investigation into cancer and nutrition. Int J Cancer, 2006, 119(10): 2412-2416

[21] PitardA., BrennanP., ClavelJ., et al.. Cigar, pipe, and cigarette smoking and bladder cancer risk in European men. Cancer Causes Control, 2001, 12(6): 551-556

[22] SamanicC., KogevinasM., DosemeciM., et al.. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev, 2006, 15(7): 1348-1354

[23] Van HemelrijckM.J., MichaudD.S., ConnollyG.N., et al.. Tobacco use and bladder cancer patterns in three western European countries. J Public Health (Oxf), 2009, 31(3): 335-344

[24] FondrevelleM.E., KantelipB., ReiterR.E., et al.. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol, 2009, 27(3): 268-276

[25] ShinV.Y., WuW.K., YeY.N., et al.. Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2. Carcinogenesis, 2004, 25(12): 2487-2495

[26] ChenR.J., HoY.S., GuoH.R., et al.. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci, 2008, 104(2): 283-293

[27] PuliyappadambaV.T., CheriyanV.T., ThulasidasanA.K., et al.. Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol Cancer, 2010, 9: 220